Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
258 hedge funds and large institutions have $3.13B invested in Amicus Therapeutics in 2024 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 104 increasing their positions, 77 reducing their positions, and 32 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 77
21% more call options, than puts
Call options by funds: $3.52M | Put options by funds: $2.9M
16% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 32
2% more funds holding
Funds holding: 254 → 258 (+4)
2.56% less ownership
Funds ownership: 108.98% → 106.42% (-2.6%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
18% less capital invested
Capital invested by funds: $3.79B → $3.13B (-$665M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.7M |
| 2 |
Millennium Management
New York
|
+$18.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$18.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.1M |
| 5 |
BlackRock
New York
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$48.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$27.3M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$26.2M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$25.6M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$14.7M |
FOLD Hedge Fund Activity: Q2 2024 in Review
258 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2024, worth a combined $3.13B — down 18% from $3.79B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new FOLD positions and 32 closed out — a net gain of 5 holders — while 104 added to existing stakes and 77 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $23.7M. The largest seller was Morgan Stanley, cutting an estimated $48.4M.
- 258 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2024, up from 254 in Q1 2024.
- Funds reported $3.13B of Amicus Therapeutics stock for Q2 2024, down 18% quarter-over-quarter.
- 37 funds opened new Amicus Therapeutics positions in Q2 2024 and 32 closed out, a net change of +5 holders.
- The largest Amicus Therapeutics buyer in Q2 2024 was Wellington Management Group, an estimated $23.7M added.
- The largest Amicus Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $48.4M sold.
Based on aggregated 13F filings for Q2 2024.